An Analysis of Ranibizumab Treatment and Visual Outcomes in Real-World Settings: The Uncover Study
Date
2018Author
Eldem, Bora
Lai, Timothy Y. Y.
Ngah, Nor Fariza
Vote, Brendan
Yu, Hyeong Gon
Fabre, Alban
Backer, Arthur
Clunas, Nathan J.
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Purpose To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia–Pacific region. Methods Non-interventional multicenter historical cohort study of intravitreal ranibizumab use for nAMD in routine clinical practice between April 2010 and April 2013. Eligible patients were diagnosed with nAMD, received at least one intravitreal ranibizumab injection during the study period, and had been observed for a minimum of 1 year (up to 3 years). Reimbursement scenarios were defined as self-paid, partially-reimbursed, and fully-reimbursed. Results More than three-fourths (n = 2521) of the analysis population was partially-reimbursed for ranibizumab, while 16.4% (n = 532) was fully-reimbursed, and 5.8% was self-paid (n = 188). The average annual ranibizumab injection frequency was 4.1 injections in the partially-reimbursed, 4.7 in the fully-reimbursed and 2.6 in the self-paid populations. The average clinical monitoring frequency was estimated to be 6.7 visits/year, with similar frequencies observed across reimbursement categories. On average, patients experienced VA reduction of −0.7 letters and a decrease in CRT of −44.4 μm. The greatest mean CRT change was observed in the self-paid group, with −92.6 μm. Conclusions UNCOVER included a large, heterogeneous ranibizumab-treated nAMD population in real-world settings. Patients in all reimbursement scenarios attained vision stability on average, indicating control of disease activity. Electronic supplementary material The online version of this article (10.1007/s00417-017-3890-8) contains supplementary material, which is available to authorized users.
URI
https://doi.org/10.1007/s00417-017-3890-8https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911274/
http://hdl.handle.net/11655/16907